| The pharmacology and clinical development of a new congestiveheart failure agent-milrinone were summarized and the technicsroutes of synthesis and purification were modified. The eligible production was prepared from 4-methyl pyridine through a three-step process. In the experiments we particularly studied the yield of l-(4-pyridinyl)acetone from 4-methyl pyridine in different material ratio , different temperature , different reaction time and optimize the reaction conditions. Then the obtained crude milrinone was purified to accord with the standard of milrinone for injection . |